CLBS Historical PE Ratio image   This CLBS PE ratio history page last updated 8/8/2022
CLBS PE History Chart
PeriodPriceGAAPTTMPE
Q2 2022
8/4/2022
0.52-0.11-0.41NA
Q1 2022
5/5/2022
0.52-0.07-0.40NA
Q4 2021
3/22/2022
0.74-0.11-0.52NA
Q3 2021
11/4/2021
1.17-0.12-0.69NA
Q2 2021
8/5/2021
1.29-0.10-0.86NA
Q1 2021
5/6/2021
1.51-0.19-1.08NA
Q4 2020
2/25/2021
1.91-0.28-1.27NA
Q3 2020
11/5/2020
1.61-0.29-1.46NA
Q2 2020
8/13/2020
2.15-0.32-1.64NA
Q1 2020
5/7/2020
1.85-0.38-1.81NA
Q4 2019
3/5/2020
2.37-0.47-1.87NA
Q3 2019
11/6/2019
2.12-0.47-1.76NA
Q2 2019
8/8/2019
2.68-0.49-1.65NA
Q1 2019
5/9/2019
2.93-0.44-1.58NA
Q4 2018
3/14/2019
4.10-0.36-1.66NA
Q3 2018
11/8/2018
5.21-0.36-1.70NA
Q2 2018
8/9/2018
5.27-0.42-1.72NA
Q1 2018
5/10/2018
4.09-0.52-1.52NA
Q4 2017
3/22/2018
6.09-0.40-2.12NA
Q3 2017
11/9/2017
3.13-0.38-2.26NA
Q2 2017
8/10/2017
3.90-0.22-2.97NA
Q1 2017
5/15/2017
5.33-1.12-4.08NA
Q4 2016
3/17/2017
5.73-0.54-5.06NA
Q3 2016
11/7/2016
3.44-1.09-10.42NA
Q2 2016
8/9/2016
6.14-1.33-11.43NA
Q1 2016
5/5/2016
7.40-2.10-13.90NA
Q4 2015
3/15/2016
8.60-5.90-17.60NA
Q3 2015
11/5/2015
13.10-2.10NANA
Q2 2015
8/6/2015
15.30-3.80NANA
Q1 2015
5/6/2015
23.80-5.80NANA
CLBS Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q2 2022
8/4/2022
0.52-0.11-0.44NA
Q1 2022
5/5/2022
0.52-0.07-0.28NA
Q4 2021
3/22/2022
0.74-0.11-0.44NA
Q3 2021
11/4/2021
1.17-0.12-0.48NA
Q2 2021
8/5/2021
1.29-0.10-0.40NA
Q1 2021
5/6/2021
1.51-0.19-0.76NA
Q4 2020
2/25/2021
1.91-0.28-1.12NA
Q3 2020
11/5/2020
1.61-0.29-1.16NA
Q2 2020
8/13/2020
2.15-0.32-1.28NA
Q1 2020
5/7/2020
1.85-0.38-1.52NA
Q4 2019
3/5/2020
2.37-0.47-1.88NA
Q3 2019
11/6/2019
2.12-0.47-1.88NA
Q2 2019
8/8/2019
2.68-0.49-1.96NA
Q1 2019
5/9/2019
2.93-0.44-1.76NA
Q4 2018
3/14/2019
4.10-0.36-1.44NA
Q3 2018
11/8/2018
5.21-0.36-1.44NA
Q2 2018
8/9/2018
5.27-0.42-1.68NA
Q1 2018
5/10/2018
4.09-0.52-2.08NA
Q4 2017
3/22/2018
6.09-0.40-1.60NA
Q3 2017
11/9/2017
3.13-0.38-1.52NA
Q2 2017
8/10/2017
3.90-0.22-0.88NA
Q1 2017
5/15/2017
5.33-1.12-4.48NA
Q4 2016
3/17/2017
5.73-0.54-2.16NA
Q3 2016
11/7/2016
3.44-1.09-4.36NA
Q2 2016
8/9/2016
6.14-1.33-5.32NA
Q1 2016
5/5/2016
7.40-2.10-8.40NA
Q4 2015
3/15/2016
8.60-5.90-23.60NA
Q3 2015
11/5/2015
13.10-2.10-8.40NA
Q2 2015
8/6/2015
15.30-3.80-15.20NA
Q1 2015
5/6/2015
23.80-5.80-23.20NA
Quotes delayed 20 minutes

Email EnvelopeFree CLBS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Caladrius Biosciences (CLBS) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CLDX PE Ratio History
CLNN PE Ratio History
CLOV PE Ratio History
CLPT PE Ratio History
CLRB PE Ratio History
CLSD PE Ratio History
CLSN PE Ratio History
CLVS PE Ratio History
CLXT PE Ratio History
CMAX PE Ratio History
On this page we presented the CLBS PE Ratio History information for Caladrius Biosciences' stock. The average CLBS PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CLBS PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CLBS PE ratio history result, against the recent PE: when this page was posted on 8/5/2022, the most recent closing price for CLBS had been 0.51, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CLBS or any other given stock, valuation analysis for CLBS can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Caladrius Biosciences PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for CLBS. Thanks for visiting, and the next time you need to research CLBS PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: MCB Average Annual Return, MILL Options Chain, OPEN Options Chain.

 

CLBS PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.